摘要 |
The present invention is concerned with a variant blood coagulation component, which is substantially homologous in amino acid sequences to a wild-type blood coagulation component capable of exhibiting anticoagulant activity in the protein C-anticoagulant system of blood and selected from protein C (PC) and activated protein C (APC), said variant component being capable of exhibiting an anticoagulant activity, that is enhanced in comparison with anticoagulant activity expressed by the corresponding wild-type blood coagulation component, said variant component differing from the respective wild-type component, in that it contains in comparison with said wild-type component at least one amino acid residue modification in it N-terminal amino acid residue sequence that constitutes the Gla-domain of protein C. The present invention is also concerned with methods to produce such variants based on DNA technology, with DNA segments intended for use in the said methods, and with use of said variants for therapeutic and diagnostic purposes.
|